肿瘤防治研究2013，Vol.40Issue(2)：185-189,5.DOI:10.3971/j.issn.1000-8578.2013.02.015
卡培他滨二线治疗非小细胞肺癌的剂量递增研究
Dose Escalation of Capecitabine as Second-line Chemotherapy for Patients with Non-small Cell Lung Cancer
摘要
Abstract
Objective To define the maximum-tolerated dose ( MTD) of capecitabine with fixed docetaxel for Chinese patients with previously treated NSCLC. Methods Escalating doses of capecitabine with fixed docetaxel were administered in a modified Fibonacci sequence. Eighteen patients received 67 cycles at capecitabine of level 1(1 250 mg/m2,divided into 625 mg/m2 ,bid) and level Ⅱ (1 500 mg/m2 750 mg/ m2 .bid). The initial doses were capecitabine 625 mg/m2 ,bid,on day d5-dl8,and docetaxel 30 mg/nr on days 1 ,8,respectively. The regimen was repeated every 21 days. If no dose-limiting toxicity (DLT) was observed,the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be one dose level below the level without DLT. Results The most common toxicities were neutropenia,hand and feet syndrome, fatigue and nausea. Eight DLTs occurred in 5 patients in the whole group,including 1 DLT in 1 patient at dose level I and 7 DLTs in 4 patients at dose level 2. Since 4 of 6 patients in level Ⅱ experienced DLTs, we declared that level I was MTD. Conclusion MTD of our es calation trial was capecitabine of 1 250 mg/(m2 o d) (625 mg/m2 ,bid) combined with docetaxel of 30mg/ m2 ,dl ,d8,repeated every 21 days. This combination regimen was well tolerated for previously treated patients with NSCLC.关键词
剂量递增/二线治疗/化疗/卡培他滨/多西紫杉醇Key words
Dose escalation/Second-line therapy/Chemotherapy/Capecitabine/Docetaxel分类
医药卫生引用本文复制引用
蔺强,赵文艳,任小沧,王娜,李彦琦,高月乔,刘月娥,赵彦南..卡培他滨二线治疗非小细胞肺癌的剂量递增研究[J].肿瘤防治研究,2013,40(2):185-189,5.基金项目
河北省科学技术厅资助项目(072761711) （072761711）
